NeoStem to acquire private US stem cell company
This article was originally published in Scrip
NeoStem, a US stem cell venture with operations in China, is to acquire Progenitor Cell Therapy, a private US firm with expertise in the manufacture of stem cell products.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.